發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本通告日期，執行董事為張鋒先生，黃劍波先生及張曉光先生，非執行董事為張翼飛先生、于琳女士及金銳先生，而獨立非執行 董事為易永發先生、潘嘉陽先生及章劍舟先生。 第 2 頁 共 2 頁 v 1.1.1 第 1 頁 共 2 頁 v 1.1.1 EF001 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 深圳市海王英特龍生物技術股份有限公司 | | 股份代號 | 08329 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度末期股息 | | 公告日期 | 2025年3月26日 | | 公告狀態 | 更新公告 | | 更新/撤回理由 更新 ...

EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 深圳市海王英特龍生物技術股份有限公司 | | 股份代號 | 08329 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度特別股息 | | 公告日期 | 2025年3月25日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 其他 | | 特別股息 | | | 股息性質 | 特別股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派股息 | 每 股 0.141 RMB | | 股東批准日期 | 有待公佈 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.141 RMB | | 匯率 ...

EF001 免責聲明 EF001 其他信息 其他信息 不適用 發行人董事 於本公告日期，執行董事為張鋒先生，黃劍波先生及張曉光先生，非執行董事為張翼飛先生、于琳女士及金銳先生，而獨立非執行 董事為易永發先生、潘嘉陽先生及章劍舟先生。 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 深圳市海王英特龍生物技術股份有限公司 | | | 股份代號 | 08329 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度末期股息 | | 公告日期 | 2025年3月25日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派 ...

Financial Performance - The company's revenue for the year ended December 31, 2024, was RMB 1,041,698,000, a decrease of 2.4% compared to RMB 1,064,861,000 in 2023[3] - Gross profit for the year was RMB 330,467,000, down 26.2% from RMB 447,511,000 in the previous year[3] - Operating profit decreased slightly to RMB 34,722,000 from RMB 36,248,000, reflecting a decline of 4.2%[3] - The net profit attributable to the owners of the company was RMB 25,014,000, an increase of 3.7% from RMB 24,127,000 in 2023[3] - Basic and diluted earnings per share increased to RMB 1.49 from RMB 1.44, representing a growth of 3.5%[3] - The company reported a total segment profit of RMB 37,179,000 for 2024, a decrease of 3.2% from RMB 38,419,000 in 2023[33] - The net profit after tax decreased to approximately RMB 13,765,000, down about 5.23% from the previous year[65] Assets and Liabilities - Total assets as of December 31, 2024, were RMB 1,398,086,000, compared to RMB 1,415,646,000 in 2023, indicating a slight decrease[4] - The company's cash and cash equivalents decreased to RMB 283,424,000 from RMB 372,206,000, a decline of 23.9%[4] - Non-current assets totaled RMB 589,059,000, an increase from RMB 495,062,000 in the previous year, reflecting a growth of 18.9%[4] - The company reported a total equity of RMB 1,026,099,000, up from RMB 1,016,182,000 in 2023, indicating a growth of 1.0%[5] - The company’s total liabilities decreased to RMB 222,377,000 in 2024 from RMB 260,527,000 in 2023, a reduction of about 14.6%[48] - Accounts receivable decreased to RMB 159,529,000 in 2024 from RMB 174,252,000 in 2023, a reduction of approximately 8.4%[46] Revenue Breakdown - Revenue from the production and sale of pharmaceuticals and medical devices was RMB 540,581,000 in 2024, down 6.3% from RMB 576,679,000 in 2023[26] - Revenue from the sale and distribution of pharmaceuticals, health products, and medical devices increased to RMB 501,117,000 in 2024, up 2.3% from RMB 488,182,000 in 2023[26] - The sales of medical devices accounted for approximately RMB 220,993,000 in 2024, compared to RMB 210,674,000 in 2023, reflecting a growth of 4.0%[27] - Revenue from hospitals was RMB 74,139,000 in 2024, while revenue from pharmacies was RMB 960,111,000, indicating a shift in sales channels[36] Expenses - Employee costs increased to RMB 163,778,000 in 2024 from RMB 148,985,000 in 2023, reflecting a rise of about 9.5%[37] - Research and development expenses decreased to RMB 33,130,000 in 2024 from RMB 46,203,000 in 2023, a decline of approximately 28.3%[39] - Sales and distribution expenses for the year were approximately RMB 162,361,000, a decrease of about 35.78% compared to the previous year[63] - Administrative expenses for the year were approximately RMB 93,912,000, an increase of 3.85% year-on-year[64] Dividends and Shareholder Information - The company plans to distribute a final dividend of RMB 0.005 per share and a special dividend of RMB 0.141 per share for 2024, totaling RMB 244,988,000[42][43] - Major shareholder Sea King Biological holds 1,181,000,000 shares, representing approximately 94.33% of domestic shares and 70.38% of total issued capital[88] - Sea King Group and Sea King Holdings each control 1,233,464,500 shares, accounting for 98.52% of domestic shares and 73.51% of total issued capital[88] Compliance and Governance - The financial statements comply with the applicable GEM Listing Rules disclosure requirements[10] - The board emphasizes adherence to corporate governance principles and has complied with applicable GEM listing rules[95] - The company has adopted a code of conduct for securities trading that meets or exceeds GEM listing rules standards[96] - The controlling shareholder, Sea King Biological, has committed not to engage in any business that competes directly or indirectly with the company[98] Future Plans and Market Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[7] - The company plans to continue transforming its marketing model and organizational structure to achieve profitability by 2025[57] - The company aims to enhance its product sales structure by shifting from traditional drug distribution to a model integrating medical services and drug distribution[57] - The company is actively expanding its market presence by participating in national procurement alliances, which could drive sales growth[56] Financial Reporting Standards - The consolidated financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards and presented in Renminbi (RMB) as the functional currency[10] - The financial statements have been prepared on a historical cost basis, with no significant impact from the adoption of revised Hong Kong Financial Reporting Standards for the current and prior periods[11][12] - The revised Hong Kong Financial Reporting Standards effective from January 1, 2024, include HKAS 1 (Amendment) related to non-current liabilities with covenants and HKFRS 16 (Amendment) concerning lease liabilities in sale and leaseback transactions[12] - The company anticipates that the newly issued and revised Hong Kong Financial Reporting Standards will not have a significant impact on the consolidated financial statements[15] Employee and Workforce - The company employed a total of 1,485 employees as of December 31, 2024, compared to 1,444 employees in 2023, indicating a focus on workforce expansion[78] - The total employee cost for the year was approximately RMB 163,778,000, an increase from RMB 148,985,000 in 2023, reflecting adjustments in salaries and benefits to maintain competitiveness[78] Research and Development - The company has a total of 368 approved drug formulations at its Fuzhou production base, with 236 included in the National Basic Medical Insurance Drug List[53] - The company holds 87 patents, including 25 invention patents, indicating a strong focus on innovation and intellectual property[54] - Five products have passed the consistency evaluation, including sodium bicarbonate tablets and norfloxacin capsules, enhancing the company's market competitiveness[54] - The company aims to obtain production approval for its self-developed drugs by 2025, which could significantly impact future revenue streams[55] Miscellaneous - There were no significant acquisitions or disposals of subsidiaries, associates, or joint ventures during the year[75] - The company reported no significant contingent liabilities as of December 31, 2024[76] - The company did not engage in any major investments or purchases of significant capital assets during the year[77] - The company has confirmed compliance with the non-competition commitment established with its controlling shareholder, Sea King Biological, during the year[94] - The group’s financial data for the year has been reviewed and is consistent with the audited consolidated financial statements[99]

深圳市海王英特龍生物技術股份有限公司（「本公司」）董事（「董事」）會（「董事會」）茲通告謹定於二零 二五年三月二十五日（星期二）上午十一時正於中華人民共和國（「中國」）廣東省深圳市南山區科技中三 路1號海王銀河科技大廈24樓會議室舉行董事會會議，以商討下列事項： 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 深圳市海王英特龍生物技術股份有限公司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* （於中華人民共和國註冊成立的股份有限公司） （股份代號：8329） 董事會會議通告 深圳市海王英特龍生物技術股份有限公司 主席 張鋒 中國深圳市，二零二五年三月五日 * 僅供識別 1 1. 審議及批准本公司及其附屬公司截至二零二四年十二月三十一日止全年的經審核綜合年度業 績，以及批准將於香港聯合交易所有限公司（「聯交所」）GEM網站及本公司網站刊登的經審核綜 合年度業績的公佈稿； ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 深圳市海王英特龍生物技術股份有限公司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* （在中華人民共和國註冊成立的股份有限公司） （股份代號：8329） 股東特別大會通告 承董事會命 茲通告深圳市海王英特龍生物技術股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）謹訂於 二零二四年十二月三十一日（星期二）上午十時正在中華人民共和國（「中國」）廣東省深圳市南山區科技 中三路1號海王銀河科技大廈24樓會議室舉行股東特別大會（「股東特別大會」），藉以考慮及酌情通過 下列決議案（無論有否修改）： 普通決議案 1 1. 「動議 (a) 批准、確認及追認本公司與深圳市海王易點藥醫藥有限公司於二零二四年十一月十五日訂 立之補充協議（「二零二三年補充易點藥代銷協議」）之形式及內容及其項下擬進行的所有交易 （二零二三年補充易點藥代銷協議註有「A」 ...

此乃要件 請即處理 閣下對本通函任何方面或應採取的行動如有任何疑問，應諮詢 閣下之持牌證券交易商或其他註 冊證券機構、銀行經理、律師、專業會計師或其他專業顧問尋求獨立意見。 閣下如已售出或轉讓名下所有深圳市海王英特龍生物技術股份有限公司的股份，應立即將本通 函連同隨附的代理人委任表格交予買主或承讓人或經手買賣或轉讓的銀行、持牌證券交易商或 其他證券註冊機構或其他代理人，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 深圳市海王英特龍生物技術股份有限公司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* 易點藥代銷協議之年度上限及提早終止； (2) 有關二零二四年易點藥代銷協議之 持續關連交易； (3) 有關續新二零二一年 藥業代銷協議之持續關連交易；及 (4) 股東特別大會通告 獨立董事委員會及 獨立股東之獨立財務顧問 （於中華人民共和國註冊成立的股份有限公司 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 深圳市海王英特龍生物技術股份有限公司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* （於中華人民共和國註冊成立之股份有限公司） （股份代號：8329） (1)修訂有關二零二三年易點藥代銷協議之年度上限； (2)終止二零二三年易點藥代銷協議； (3)有關二零二四年易點藥代銷協議之持續關連交易； 及 (4)有關續新二零二一年藥業代銷協議之持續關連交易 獨立董事委員會及獨立股東之獨立財務顧問 1. 二零二三年易點藥代銷協議 茲提述本公司日期為二零二三年十二月二十八日有關二零二三年現有易點藥代銷協議之公 告。 自二零二三年現有易點藥代銷協議開始起，本公司出售之藥品、食品、保健食品及醫療設備 於中國市場廣受歡迎且銷量增長速度高於預期。於二零二四年一月一日起至二零二四年十月 三十一日止期間，二零二三年現有易點藥代銷協議項下之銷售總額約為人民幣9 ...

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 544,504,000, a decrease of 2% compared to RMB 555,531,000 in the same period of 2023[4]. - Gross profit for the reporting period was RMB 194,966,000, down 20.4% from RMB 245,316,000 in the previous year[4]. - Profit from operations increased to RMB 50,761,000, representing a 27.8% rise from RMB 39,721,000 in 2023[4]. - Profit before taxation was RMB 48,292,000, up 32.4% from RMB 36,474,000 in the same period last year[4]. - Net profit attributable to owners of the Company was RMB 37,907,000, an increase of 26.9% compared to RMB 29,881,000 in 2023[5]. - Basic and diluted earnings per share rose to RMB 2.26 cents, compared to RMB 1.78 cents in the previous year[5]. - Total comprehensive income for the period was RMB 41,254,000, up from RMB 31,090,000 in 2023[4]. - The company reported a profit of RMB 37,907,000 for the six months ended June 30, 2024, compared to RMB 29,881,000 for the same period in 2023, indicating a year-over-year increase of about 26.8%[9]. Assets and Liabilities - Current assets as of June 30, 2024, totaled RMB 930,660,000, compared to RMB 920,584,000 at the end of 2023[6]. - Non-current assets amounted to RMB 494,344,000, slightly down from RMB 495,062,000 at the end of 2023[6]. - As of June 30, 2024, net current assets increased to RMB 599,878,000 from RMB 554,404,000 at the end of 2023, representing an increase of approximately 8.2%[7]. - Total equity rose to RMB 1,057,436,000 as of June 30, 2024, compared to RMB 1,016,182,000 at the end of 2023, marking an increase of about 4.1%[8]. - The company generated RMB 21,217,000 from operating activities in the first half of 2024, compared to a cash outflow of RMB 52,320,000 in the same period of 2023, indicating a significant turnaround[10]. - Cash and cash equivalents at the end of the period were RMB 311,947,000, up from RMB 237,442,000 at the end of June 2023, representing a growth of approximately 31.4%[11]. - Interest-bearing borrowings decreased slightly to RMB 83,780,000 as of June 30, 2024, from RMB 85,417,000 at the end of 2023, a reduction of about 1.9%[7]. - The company’s total assets less current liabilities increased to RMB 1,094,222,000 from RMB 1,049,466,000, reflecting an increase of approximately 4.3%[7]. Revenue Breakdown - Revenue from manufacturing and selling of medicines and medical devices was RMB 295,150,000, down 27.5% from RMB 407,492,000 in 2023[17]. - Revenue from sales and distribution of medicines, healthcare products, and medical devices increased by 68.3% to RMB 249,354,000 from RMB 148,039,000 in 2023[17]. - Total revenue from manufacturing and selling medicines and medical devices was RMB 295,150,000 for the six months ended June 30, 2024, down from RMB 407,492,000 in 2023, reflecting a decrease of approximately 27.5%[30]. - Revenue from the sales of medicines and healthcare products decreased to RMB 423,917,000 for the six months ended June 30, 2024, down from RMB 446,340,000 in the same period of 2023, representing a decline of approximately 5.5%[29]. - Sales of medical devices increased to RMB 120,587,000 for the six months ended June 30, 2024, compared to RMB 109,191,000 in the same period of 2023, marking an increase of about 10.8%[29]. Expenses and Costs - The Group's total cost of inventories for the six months ended June 30, 2024, was RMB 338,296,000, compared to RMB 297,569,000 in 2023, reflecting an increase of approximately 13.7%[33]. - The Group's selling and distribution expenses were approximately RMB 82,983,000, representing a decrease of approximately 43.84% from approximately RMB 147,759,000 for the corresponding period of last year[134]. - The Group's other operating expenses and impairment/reversal on trade and other receivables, net amounted to approximately RMB 25,546,000, representing an increase of approximately 12.96% from approximately RMB 22,615,000 for the corresponding period of last year[135]. - Research and development costs increased to RMB 18,057,000 for the six months ended June 30, 2024, compared to RMB 14,518,000 in the same period of 2023, representing an increase of approximately 24.5%[35]. Taxation - The current tax expense for the six months ended June 30, 2024, was RMB 8,378,000, up from RMB 5,896,000 in 2023, indicating an increase of about 42.2%[38]. - The Group's tax rate for its subsidiaries in China is 25%, while three subsidiaries qualified for a reduced tax rate of 15% as "high-tech enterprises"[40]. Corporate Governance and Structure - The Company has adopted a code of conduct regarding securities transactions by Directors, ensuring compliance with GEM Listing Rules[158]. - The Company established an Audit Committee on 21 August 2005, responsible for reviewing annual reports and financial statements[162]. - The roles of the Chairman and General Manager are separate, with Mr. Zhang Feng serving as the current Chairman[162]. - The Company aims to enhance its corporate governance standards continuously[162]. Related Party Transactions - Related party transactions included sales of goods to Shenzhen Neptunus Pharmaceutical Company Limited totaling RMB 28,847,000 for the six months ended June 30, 2024, compared to RMB 30,336,000 in 2023[59]. - The company engaged in related party transactions, with total sales of goods to related parties amounting to RMB 2,489,000 from Jilin Neptunus Jiankang Technology Development Company Limited in 2024, down from RMB 4,233,000 in 2023, a decrease of 41.3%[79]. - The total amounts due from related parties reached RMB 54,123,000 as of June 30, 2024, compared to RMB 44,363,000 at December 31, 2023, reflecting a growth of 22%[114]. Shareholding and Capital Structure - As of June 30, 2024, Neptunus Bio-engineering held approximately 73.51% of the entire issued share capital of the Company, with 70.38% directly held and 3.13% indirectly held through Shenzhen Neptunus Oriental Investment Company Limited[152]. - Neptunus Bio-engineering directly owned 1,181,000,000 domestic shares, representing 94.33% of all domestic shares and approximately 70.38% of the Company's issued share capital[154]. - The Company has maintained a stable ownership structure with substantial shareholders holding significant percentages of the issued share capital[154]. Operational Developments - The Group operates two pharmaceutical production bases in Fuzhou and Beijing, with Fuzhou holding 366 approval documents for various medicines, including 207 listed in the National Medical Insurance Catalogue[123]. - The Group continues to invest in the research and development of new medicines and the consistency evaluation of generic medicines[124]. - Neptunus Zhongxin is undergoing operational transformation, including marketing model changes and organizational restructuring, to improve profitability[131].

1 深圳市海王英特龍生物技術股份有限公司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* （於中華人民共和國註冊成立之股份有限公司） （股份代號：8329） 截至二零二四年六月三十日止六個月 之中期業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於 該等公司的潛在風險，並應經過審慎周詳的考慮後方可作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於聯交所主板買賣之證券承受較大的市場波動風險，同時無法保證在GEM買 賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告的資料乃遵照聯交所的《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供有關深圳市海王英特龍生物技術股份有限公司（「本公司」） 的資料。 ...